[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Spaulding Rehabilitation Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":585},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,24,0,[8,51,73,100,123,156,177,191,211,229,259,282,308,329,354,379,407,434,456,477,502,528,547,567],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100053720","at-home-wearable-sensors-and-smartphone-for-stroke-survivors-with-upper-limb-motor-challenges-100053720",false,"NCT06787729","At Home Wearable Sensors and Smartphone for Stroke Survivors With Upper Limb Motor Challenges.","Motivation-Induced Movement Therapy: Enhancing Upper Limb Engagement in Stroke Survivors Through Ring Sensors and Data Visualization.","Inclusion Criteria:\n\n* Stroke survivor (ischemic or hemorrhagic), \\>12 months post stroke, at the time of consent\n* Aged between 18 and 80\n* Ability to extend ≥ 10° at the metacarpophalangeal joint and one of the interphalangeal joints of each finger, ≥ 10° extension or abduction of the thumb, and ≥ 20° extension of the wrist from a fully flexed starting position.\n* Demonstrating more affected arm nonuse, defined as a MAL-AoU score of \\\u003C\u002F= 4.5.\n* Actively uses at least one smartphone app.\n* Strong beliefs towards being in control of their recovery, indicated by a score of ≤ 10 points on the Internal Recovery Locus of Control (I-RLOC) Scale.\n* Participants must be able to read, write, and understand English at a level sufficient to comprehend study materials and provide informed consent.\n\nExclusion Criteria:\n\n* Cognitive impairments that may affect the ability to understand and follow instructions (score \\\u003C 24 in the Mini Mental State Examination)\n* Difficulties comprehending numbers, dyslexia, severe aphasia, or other neurological conditions that prohibit the use of smartphones for safety reasons.\n* Undergoing other types of motor therapy during the study period.\n* Previous participation in constraint-induced movement therapy.\n* Currently participating in or has participated in the past 3 months in any experimental rehabilitation or drug studies.\n* Use of botulinum toxin for motor disability ≤ 3 months before treatment.\n* Significant changes in pharmacological or treatment plans during the study period that may affect upper-limb use.\n* Major medical problems that could interfere with participation.\n* History of a disabling stroke (i.e., need more than minimum assistance to perform ADLs).\n* Legally blind status.\n* Uncontrolled seizures.\n* Inability to don\u002Fdoff sensors independently or with the assistance of a caregiver.\n* Implantable medical devices that do not comply with the ISO 14117:2012 and\u002For ANSI\u002FAAMI PC69 standards for electromagnetic compatibility. Subjects will be asked to provide their medical device record card, and non-compliant devices will result in exclusion from the study.","ALL","18 Years","80 Years",{"count":20,"type":21},50,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this clinical trial is to learn if wearable sensor data visualization on smartphones can improve the use of the stroke-affected limb during everyday activities. Chronic stroke survivors (\\>12 months from onset) ages 18-80 years old with residual upper extremity motor impairments may be eligible to participate. The main question it aims to answer is:\n\nDoes the mobile health (mHealth) intervention help to improve the use of the stroke-affected upper-limb during daily living?\n\nThe study is designed so each participant serves as their own control. Researchers will compare information from the baseline and intervention time periods to see if visualizing the data on the smartphone impacts the participant's daily use of the arm.\n\nParticipants will be asked to wear a set of wearable ring and wrist sensors and interact with a custom-designed smartphone app, aiming to increase the use of their stroke-affected limb during daily activities as much as possible. They will receive feedback from the app, communicate with study therapists, participate in goal setting, complete clinical assessments, and share about their experience using the system during a virtual interview.",[27],"Stroke",[29,30,31,32,33,34,35,36,27,37],"Hemiparesis","Upper extremity","Weakness","Arm","Hand","Ring Sensor","Wrist Sensor","mHealth","Activities of daily living","RECRUITING","2026-07-10",{"date":41,"type":42},"2026-07-13","ACTUAL",{"date":44,"type":42},"2026-04-20",{"date":46,"type":21},"2027-07-31",{"name":48,"class":49},"Spaulding Rehabilitation Hospital","OTHER",1,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":16,"minAge":57,"maxAge":18,"enrollmentInfo":58,"targetDuration":4,"studyType":22,"phases":60,"briefSummary":61,"conditions":62,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":4},"100644659","probing-gut-brain-communication-in-parkinsons-disease-100644659","NCT07673146","Probing Gut-Brain Communication in Parkinson's Disease","Inclusion Criteria:\n\n* Aged ≥21 years old and ≤80 years old\n* Clinical diagnosis of PD as defined by Movement Disorder Society (MDS) PD Criteria\n* Adequate visual, hearing, cognitive, and physical ability\n\nExclusion Criteria:\n\n* Diagnosis of secondary or atypical parkinsonism\n* Laboratory Values: a: Hemoglobin (Hgb) \\\u003C10; b: Platelets \\\u003C70,000; c: Alanine Transaminase (ALT) or Aspartate Aminotransferase (AST) \\> 2 1\u002F2 times upper limit of normal (ULN); d: Moderate or severe renal disease with an estimated glomerular filtration rate (eGFR) \\\u003C60 mL\u002Fmin\u002FBSA \\[body surface area\\] calculated using the Chronic Kidney Disease-Epidemiology Collaboration (CKD-EPI) equation, or moderate or severe hepatic impairment (alkaline phosphatase \\[ALP\\] \\>2.0 times the ULN and\u002For total bilirubin \\>2.0 times the ULN); e: Significantly above the normal range for PT\u002FINR\u002FPTT.\n* Clinically significant cognitive impairment with a Montreal Cognitive Assessment (MOCA) score 35 kg\u002Fm2 or body weight\n* Clinical or laboratory findings consistent with another primary neurodegenerative disease or cognitive disorder other than PD, including but not limited to, frontotemporal lobar disease, Huntington's disease, progressive supranuclear palsy, multisystem atrophy, Creutzfeld-Jakob- Disease, Down's syndrome, cortico-basal degeneration, dementia with Lewy Bodies, Alzheimer's disease, amyotrophic lateral sclerosis, seizure disorder, stroke, or other infectious, metabolic, or systemic disease affecting the central nervous system including, but not limited to, syphilis, present hypothyroidism, present or unaddressed\u002Ftreated vitamin B12 deficiency, or other screening laboratory abnormalities\n* Suicidality, defined as active suicidal thoughts or ideation within 6 months before Screening or at Baseline, defined as answering yes to items 4 or 5 on the Columbia-Suicide Severity Rating Scale (C-SSRS), or history of suicide attempt in previous 2 years, or, in the Investigator's opinion, at serious risk of suicide\n* Has cancer or has had a malignant tumor within the past 5 years. (Participants with stable untreated prostate cancer or treated cutaneous squamous or basal cell carcinomas are not excluded.)\n* Any medical condition or systemic disease that, in the Investigator's opinion, may either put the participant at risk because of participation in the study, influence the results or proposed analyses, or impair the participant's ability to fully participate in the study\n* Body weight \\> 400lbs (limit of the MRI table)\n* Participant is currently pregnant, breastfeeding, and\u002For lactating\n* History of alcohol or substance abuse or dependence within the past 2 years (DSM IV criteria)\n* History of Covid-19 (SARS-CoV-2) infection within 6 weeks prior to screening.\n* Participants with unresolved symptoms of Covid-19 infection or ongoing cognitive or other deficits attributable to post-Covid-19 that may affect participant safety or interfere with cognitive assessments based on the Investigator's clinical judgment\n* Either ongoing or current participation in another clinical trial with an investigational agent and have taken at least one dose of study medication, unless unblinded on placebo, within 4 weeks prior to the start of screening, or five half-lives of the investigational drug, whichever is greater. The end of a previous investigational trial is the date the last dose of an investigational agent was taken. Participation in other research studies (e.g., observational studies) may be acceptable throughout this study.\n* History of GI surgery. (However, patients with appendicectomy, hemorrhoid surgery, and cholecystectomy will be eligible to participate).\n* Use of medications that impact the microbiota including antibiotics during the 4 weeks prior to enrollment\n* Regular use of medication that impacts the intestinal barrier (e.g., NSAID more than 3 times weekly)\n* Endorses any contraindications to MRI (see risks section of protocol for full list of MRI exclusions)\n* Allergic to pineapple","21 Years",{"count":59,"type":21},45,[24],"Administering transcutaneous vagus nerve stimulation in patients with Parkinson's disease to see how it affects stomach and brain activity.",[63],"Parkinson Disease (PD)","NOT_YET_RECRUITING","2026-06-30",{"date":67,"type":42},"2026-07-02",{"date":69,"type":21},"2026-08-01",{"date":71,"type":21},"2031-07-01",{"name":48,"class":49},{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":16,"minAge":57,"maxAge":80,"enrollmentInfo":81,"targetDuration":4,"studyType":22,"phases":83,"briefSummary":85,"conditions":86,"keywords":88,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":50},"100521227","early-phase-1-mdma-assisted-therapy-for-fibromyalgia-100521227","NCT06066853","MDMA-assisted Therapy for Fibromyalgia","Hyperscan Neuroimaging to Reveal the Brain Mechanisms Supporting Analgesia Following MDMA-assisted Therapy for Fibromyalgia","Inclusion Criteria:\n\n* Are at least 21 years to 65 years of age inclusive, at the time of signing the informed consent.\n* Have a clinical diagnosis of fibromyalgia and meet the Wolfe et al 2011 research criteria for fibromyalgia for at least one year.\n* Typical fibromyalgia pain intensity of 4\u002F10 or greater.\n* Fluent in speaking and reading English.\n* Able to swallow pills.\n* Agree to have some study visits audiovisually recorded, including Experimental Sessions\u002F neuroimaging sessions.\n* Able to provide a contact (relative, spouse, close friend, or other support person) who is willing and able to be reached by the investigators in the event of the participant becoming unwell or unreachable.\n* Able to identify appropriate support person(s) to stay with the participant on the evenings of the Experimental Sessions\n* Have a body weight of at least 45 kilograms (kg). Participants with a body weight of 45 to 48 kg must also have a body mass index (BMI) within the range of 18 to 30 kg\u002Fm2\n* Participants assigned female sex at birth must not be pregnant or become pregnant throughout participation in the study\n* Capable of giving signed informed consent\n* Are on stable doses of allowable medication for 30 days prior to entering the study and agree not to change medications or dosages during the trial, except for medications falling under the tapering scheduling\n\nExclusion Criteria:\n\n* Presence of any medical or psychiatric illness that is judged to interfere with the study (ex. Fibromyalgia, PTSD, bipolar, schizophrenia) determined by a self-report measure.\n* Presence of any contraindications to fMRI scanning or EEG scanning. (ex. Cardiac pacemaker, metal implants, fear of enclosed spaces, pregnancy).\n* Unwillingness to receive brief experimental pain\n* Lower extremity pain or vascular issues that may interfere with the study procedures\n* Current unstable liver or biliary disease per investigator assessment defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, persistent jaundice, or cirrhosis.\n* Have a history of any medical condition that could make receiving a sympathomimetic drug harmful because of increases in blood pressure and heart rate. This includes, but is not limited to, a history of myocardial infarction, cerebrovascular accident, heart failure, severe coronary artery disease, or aneurysm.\n* Have a diagnosis of uncontrolled hypertension, defined as repeated blood pressure readings of ≥140 mmHg systolic or ≥90 mmHg diastolic.\n* Have a history of ventricular arrhythmia at any time, other than occasional premature ventricular contractions (PVCs) in the absence of ischemic heart disease.\n* Have Wolff-Parkinson-White syndrome or any other accessory pathway that has not been successfully eliminated by ablation.\n* Have a history of arrhythmia, other than premature atrial contractions (PACs) or occasional PVCs in the absence of ischemic heart disease, within 12 months of screening.\n* Have a history of additional risk factors for Torsade de pointes (e.g., heart failure, hypokalemia, family history of Long QT Syndrome).\n* Have engaged in a new form of psychiatric or mental health care within 12 weeks of enrollment, including Electroconvulsive Therapy (ECT), and ketamine-assisted therapy.\n* Have a current moderate or severe alcohol or cannabis use disorder within the 12 months prior to enrollment.\n* Have an active illicit drug (other than cannabis) or prescription drug substance use disorder at any severity within 12 months prior to enrollment.\n* Any participant presenting current serious suicide risk, as determined through psychiatric interview, responses to C-SSRS, and clinical judgment of the investigator will be excluded; however, history of suicide attempts is not an exclusion.\n* Unable or unwilling to safely taper-off prohibited psychiatric and non-psychiatric medication with exceptions determined by study staff or require use of prohibited medications during experimental sessions.\n* Require use of concomitant medications that could prolong the QT interval during Experimental Sessions.\n* Have used Ecstasy (unregulated material represented as containing MDMA) more than 10 times within the last 10 years, or at least once within 6 months of the first Experimental Session.\n* Current enrollment in any other clinical study involving an investigational study treatment or any other type of medical research, unless approved by the study clinician.\n* Have current Personality and\u002For Psychotic Disorders.\n* Have a current eating disorder with compensatory behaviors.\n* Have current major depressive disorder with psychotic features.\n* Have a history of, or a current primary psychotic disorder, bipolar affective disorder type 1.\n* Sensitivity to any of the study interventions, or components thereof, or drug or other allergy that, in the opinion of the sponsor-investigator or study clinician, contraindicates participation in the study.\n* Are currently engaged in compensation litigation whereby financial gain would be achieved from prolonged symptoms of fibromyalgia or any psychiatric disorders.\n* Lack social support or lack a stable living situation.\n* Previous participation in a MAPS-sponsored MDMA clinical trial.\n* Employees (and their immediate family members) of MAPS, MAPS Public Benefit Corporation, or MAPS Europe B.V; or individuals in a personal relationship with the site investigator.\n* Presence of any medical or psychiatric illness that is judged to interfere with trial\n* Presence of any contraindications to fMRI scanning or EEG scanning (ex. Cardiac pacemaker, metal implants, fear of closed spaces)\n* Lower extremity pain or vascular issues that may interfere with study procedures\n* Comorbid chronic pain condition that is rated by the subject as more painful than fibromyalgia\n* Have any severe anxiety disorders or significant anxiety symptoms interfering with fMRI scanning (e.g. panic)\n* Is a current patient of the matched dyad clinician enrolled in the study\n* Would present a serious risk to others as established through clinical interview and contact with treating psychiatrist.\n* Have any current problem which, in the opinion of the sponsor-investigator or study clinician, might interfere with study participation or prevent satisfactory completion of study protocol.","65 Years",{"count":82,"type":21},20,[84],"EARLY_PHASE1","Fibromyalgia is a debilitating chronic pain disorder. Based on prior research with MDMA, it can be hypothesized MDMA-assisted therapy in fibromyalgia patients may increase the range of positive emotions, interpersonal trust, and heighten the state of empathic rapport that can lead to an enhanced patient-clinician interaction and to initiate reattribution processes targeting dysfunctional thoughts towards pain. Therapeutic alliance, i.e. a positive patient-clinician relationship, is already acknowledged as an essential component for MDMA-assisted therapy. Despite its importance, the patient-clinician interaction and the neuroscience supporting patient\u002Fclinician therapeutic alliance has received almost no attention in MDMA research. The investigators will examine the potential therapeutic benefit of MDMA-assisted therapy for fibromyalgia. Additionally, this study will also target secondary objectives including the investigation of the clinical and physiological response (i.e. brain-to-brain concordance) supporting enhanced patient-clinician therapeutic alliance in fibromyalgia patients. The study includes two Experimental Sessions of therapy with MDMA combined with neuroimaging, along integrative therapy, baseline neuroimaging, and a 3 month follow up.",[87],"Fibromyalgia",[89,87,90,91],"N-Methyl-3,4-methylenedioxyamphetamine","MDMA","Pain","2026-06-24",{"date":94,"type":42},"2026-06-29",{"date":96,"type":21},"2026-07-01",{"date":98,"type":21},"2026-12",{"name":48,"class":49},{"id":101,"slug":102,"hasResults":11,"nctId":103,"briefTitle":104,"officialTitle":105,"acronym":4,"eligibilityCriteria":106,"healthyVolunteers":11,"sex":16,"minAge":57,"maxAge":18,"enrollmentInfo":107,"targetDuration":4,"studyType":22,"phases":108,"briefSummary":109,"conditions":110,"keywords":111,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":50},"100638323","early-phase-1-relying-on-pharmacotherapy-to-improve-motor-gains-in-chronic-stroke-survivors-100638323","NCT07588932","Relying on Pharmacotherapy to Improve Motor Gains in Chronic Stroke Survivors","Relying on Pharmacotherapy to Improve Motor Gains of Robot-Assisted Upper-Extremity Rehabilitation in Chronic Stroke Survivors","Inclusion Criteria:\n\n* Adults between 21 and 80 years of age.\n* History of ischemic stroke.\n* Stroke occurred at least six months prior to recruitment.\n* Moderate to severe UE impairment (FMA-UE score between 15 and 40)\n* MMSE score \\>=20 and being able to safely follow three-step commands.\n\nExclusion Criteria:\n\n* Contraindications to the pharmacotherapy (e.g., heart failure, known medication reaction or interactions with ongoing medication regimen).\n* Taking dual antiplatelet therapy (e.g., Aspirin+Plavix) and\u002For other anticoagulation medications (e.g., Eliquis, coumadin) that cannot safely be modified or discontinued (as determined by the participant's primary care physician or by the medical monitor).\n* Clinically significant somnolence and\u002For depression that would hinder active participation in motor training sessions.\n* Taking any medication that the study physician determines to have a significant drug-drug interaction with Telmisartan, Cilostazol, and\u002For Metformin.\n* Taking Telmisartan, Cilostazol, and\u002For Metformin in a dose that is different from the one used in the study and that cannot be adjusted to match the study dose (as determined by the participant's primary care physician or by the medical monitor).\n* Taking medications with equivalent clinical effect (e.g., BP control) to Telmisartan, Cilostazol, and\u002For Metformin and that cannot be replaced by Telmisartan, Cilostazol, and\u002For Metformin (as determined by the participant's primary care physician or by the medical monitor).\n* A body mass index (BMI) below 25 (as the proposed pharmacotherapy could cause hypoglycemia in participants with normal-low BMI).\n* Severe musculoskeletal pathology or recent fractures affecting the impaired UE that would prevent safe use of the rehabilitation robotic system.\n* Previous diagnosis of neurological diseases other than stroke that would have a negative impact on the response to the rehabilitation intervention (e.g., severe dystonia affecting the UE) or would prevent safe participation in RA UE training (e.g., uncontrolled seizures).\n* Moderate to severe disability due to migraines as determined using the Migraine Disability Assessment test (score \\> 10).\n* Severe spasticity (Modified Ashworth Scale for spasticity ≥ 3 for UE muscles) that would prevent safe use of the robotic system utilized during training.\n* Undergoing Botox treatment for pain\u002Fspasticity related to the affected upper extremity, in the 4 months prior to enrollment or during the study period.\n* Cerebellar and\u002For hemorrhagic stroke.\n* Severe aphasia limiting the ability to express needs or discomfort verbally or non-verbally.\n* Visual impairments that would prevent proper use of interactive on-screen games during RA UE training.\n* Severe hemispatial neglect as assessed using the Line Bisection Test (missed lines \\>2).\n* Severely impaired trunk control that would prevent sitting safely on a chair without arms.\n* Individuals who present with the following on the impaired UE: open wounds, fragile skin, and under contact precautions due to an active infection.\n* Participation in another therapy focused on the recovery of the impaired UE.\n* Subjects with cardiac pacemakers, electronic pumps, or any other implanted medical devices that are not US-certified (and hence might be affected by the electromagnetic interference generated by the robot).\n* Any condition that would prevent proper\u002Fsafe use of the robotic system, such as proprioceptive deficits that impair the ability to process haptic or visual feedback, or unstable shoulder joint as assessed by physical examination.\n* Current pregnancy.",{"count":20,"type":21},[84],"The goal of this trial is to study if the concomitant administration of Telmisartan, Cilostazol IR (immediate release), and Metformin ER (extended release) can help stroke survivors make greater gains in movement and recovery during robot-assisted arm and hand rehabilitation.",[27],[27,112,113,114],"Rehabilitation","Pharmacotherapy","Robotic therapy","2026-05-14",{"date":117,"type":42},"2026-05-15",{"date":119,"type":21},"2026-05-18",{"date":121,"type":21},"2028-12-31",{"name":48,"class":49},{"id":124,"slug":125,"hasResults":11,"nctId":126,"briefTitle":127,"officialTitle":128,"acronym":4,"eligibilityCriteria":129,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":80,"enrollmentInfo":130,"targetDuration":4,"studyType":22,"phases":132,"briefSummary":133,"conditions":134,"keywords":141,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":155,"locationsCount":50},"100630103","extracorporeal-shockwave-therapy-and-platelet-rich-plasma-for-midportion-achilles-tendinopathy-100630103","NCT07483320","Extracorporeal Shockwave Therapy and Platelet-Rich Plasma for Midportion Achilles Tendinopathy","A Randomized Controlled Trial Evaluating the Influence of Physical Therapy, Shockwave Therapy, Platelet Rich Plasma or Combined Treatment in the Management of Midportion Achilles Tendinopathy","Inclusion Criteria:\n\n* Age 18-65 years\n* Diagnosis of unilateral midportion Achilles tendinopathy\n* Symptoms present for more than 3 months\n* VISA-A score \\\u003C80 at baseline\n* Pre-injury physical activity level ≥3 on the Physical Activity Scale\n* Ability to participate in rehabilitation program\n\nExclusion Criteria:\n\n* Symptoms present for less than 3 months\n* Prior PRP injection or ESWT treatment to the Achilles tendon within 3 months\n* Other lower extremity musculoskeletal injury affecting function\n* Symptomatic arthritis affecting the ankle or foot\n* Rheumatologic disease or connective tissue disorder\n* Coagulopathy or anticoagulant therapy affecting platelet function\n* Neuropathy affecting pain perception\n* Known cardiac condition contraindicating treatment\n* Poorly controlled diabetes (HbA1c \\>9.0)\n* Pregnancy",{"count":131,"type":21},100,[24],"Midportion Achilles tendinopathy is a common cause of pain and functional limitation in both athletes and the general population. Progressive tendon loading programs are considered first-line treatment but do not lead to satisfactory outcomes in all patients. Extracorporeal shockwave therapy (ESWT) and platelet-rich plasma (PRP) injections are commonly used interventions for refractory symptoms, yet evidence supporting their combined use is limited particularly in treating Achilles tendon disorders.\n\nThis randomized controlled trial will evaluate the effectiveness of a standardized exercise program alone or in combination with PRP injection, ESWT, or both therapies in active adults with midportion Achilles tendinopathy. Participants will be randomized to one of four treatment groups and followed for six months. The primary outcome will assess changes in Achilles tendon symptoms and function using the Victorian Institute of Sport Assessment-Achilles (VISA-A) score. Secondary outcomes will include patient-reported outcomes, physical function testing, ultrasound tendon structure measures, and gait biomechanics.",[135,136,137,138,139,140],"Achilles Injuries Tendon","Achilles Tendinopathy (AT)","Achilles Tendinitis, Left Leg","Achilles Tendinitis, Right Leg","Achilles Tendon Pain","Achilles Tendonitis",[142,143,144,145,146,147],"PRP","platelet rich plasma","extracorporeal shockwave","focus shockwave","radial pressure waves","rehabilitation","2026-05-08",{"date":150,"type":42},"2026-05-13",{"date":152,"type":21},"2026-06-01",{"date":154,"type":21},"2028-05-30",{"name":48,"class":49},{"id":157,"slug":158,"hasResults":11,"nctId":159,"briefTitle":160,"officialTitle":160,"acronym":4,"eligibilityCriteria":161,"healthyVolunteers":11,"sex":16,"minAge":57,"maxAge":18,"enrollmentInfo":162,"targetDuration":4,"studyType":22,"phases":164,"briefSummary":165,"conditions":166,"keywords":167,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":169,"lastUpdatePostDateStruct":170,"startDateStruct":172,"completionDateStruct":174,"leadSponsor":176,"locationsCount":50},"100277824","assessment-of-a-physio-neuro-platform-synphne-for-home-based-retraining-of-hand-function-in-stroke-survivors-100277824","NCT02896348","Assessment of a Physio-neuro Platform (SynPhNe) for Home-based Retraining of Hand Function in Stroke Survivors","Inclusion Criteria:\n\n* Ischemic or hemorrhagic stroke at least 6 months prior study enrollment ;\n* Moderate upper-extremity hemiparesis (initial score on the Upper Extremity Fugl-Meyer Assessment between 21 and 55 out of 66) ;\n* Ability to extend at least 2 fingers in the affected hand 10 degrees at any joint with pain-free passive range of motion at least 50% in all joints below the elbow.\n\nExclusion Criteria:\n\n* Cognitive impairment resulting to inability to follow instructions (as assessed with the MMSE) and inability to sustain attention for more than 10 minutes;\n* Current participation in upper-extremity therapy program;\n* Treatment with Botox injections in the affected arm in the previous 3 months and no planned Botox injections before the end of the study;\n* Aphasia sufficient to limit comprehension and completion of the treatment protocol;\n* No more than moderate impairments in paretic UE sensation, passive range of motion, and pain that would limit ability to engage in therapy;\n* Increased muscle tone as indicated by score of \\>\u002F= 3 on the Modified Ashworth Scale;\n* Previous diagnosis of dementia;\n* Previous diagnosis of neurological diseases other than Stroke;\n* History of seizures disorder and\u002For a seizure occuring within the last 6 months;\n* Other conditions affecting function of the stroke affected upper limb;\n* Severe pain in the stroke affected upper limb;\n* Terminal diseases with expected survival \\\u003C1 year;",{"count":163,"type":21},40,[24],"The goal of this study is to:\n\n1. Assess the usability of the SynPhNe device in a home environment.\n2. Evaluate the efficacy of the SynPhNe home use device to improve motor hand function in chronic stroke subjects as compared to standard care alone.",[27,29],[29,27,112,168],"Home-based","2026-05-04",{"date":171,"type":42},"2026-05-06",{"date":173,"type":42},"2025-02-26",{"date":175,"type":21},"2027-03",{"name":48,"class":49},{"id":178,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":179,"targetDuration":4,"studyType":22,"phases":180,"briefSummary":25,"conditions":181,"keywords":182,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":183,"lastUpdatePostDateStruct":184,"startDateStruct":186,"completionDateStruct":188,"leadSponsor":190,"locationsCount":50},"100576625",{"count":20,"type":21},[24],[27],[29,30,31,32,33,34,35,36,27,37],"2026-04-16",{"date":185,"type":42},"2026-04-21",{"date":187,"type":21},"2026-04",{"date":189,"type":21},"2027-07",{"name":48,"class":49},{"id":192,"slug":193,"hasResults":11,"nctId":194,"briefTitle":195,"officialTitle":196,"acronym":4,"eligibilityCriteria":197,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":198,"targetDuration":4,"studyType":22,"phases":200,"briefSummary":201,"conditions":202,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":203,"lastUpdatePostDateStruct":204,"startDateStruct":206,"completionDateStruct":208,"leadSponsor":210,"locationsCount":4},"100434686","burtvision-for-arm-rehabilitation-in-chronic-stroke-survivors-100434686","NCT04940403","BurtVision™ for Arm Rehabilitation in Chronic Stroke Survivors:","BurtVision™ for Arm Rehabilitation in Chronic Stroke Survivors: a Comparison of Unimanual vs. Unimanual and Bimanual Tasks During Robot-assisted Arm Training","Inclusion Criteria:\n\n1. Male or female, 18-80 years old;\n2. Unilateral ischemic or hemorrhagic stroke at least 6 months and no more than 5 years prior to study enrollment;\n3. Upper extremity hemiparesis as characterized by initial scores on upper limb subtest of the Fugl-Meyer Assessment (FMA-UE) between 12 and 40;\n4. Some active pro-supination range of motion;\n5. Some active metacarpal-phalangeal joint in the hemiparetic hand;\n6. Intact cognitive function to understand the robotic therapy procedures (MMSE\\>23 and able to follow 3 step command) during initial evaluation visit;\n\nExclusion Criteria:\n\n1. Undergoing upper-limb rehabilitation therapy during the period of the study.\n2. Severe spasticity (defined as a Modified Ashworth scale score of 3 or more) that would prevent safe use of the robotic system;\n3. Visual impairments as assessed by the NIH Stroke Scale Visual Field subscale (only subjects with no visual loss will participate in the study); or hemispatial neglect that would impair the subject's ability to play the interactive games (as assessed with the line bisection test);\n4. Severe proprioceptive deficits that impair the ability to process haptic or visual feedback, as assessed by physical examination during screening;\n5. Communication impairments such aphasia that impair the subject's ability of providing feedback (as reported by a physician in his\u002Fher medical record);\n6. Individuals with open wounds or recent fracture (\\\u003C3 months) in the upper extremity, fragile skin or active infection;\n7. Upper-extremity orthopedic injuries or severe pain resulting in movement limitations.",{"count":199,"type":21},38,[24],"The focus of this study is to perform a preliminary assessment of the efficacy of the BurtVision system. While the Burt robotic-arm assists the patient's upper-limb in their movements, BurtVision will allow the patient to perform unimanual and bimanual activities while leveraging augmented reality games. The investigators will compare clinical outcomes when the BurtVisions ystem is used for training solely relying on unimanual tasks vs. when it is used for training relying on both unimanual and bimanual tasks.",[27],"2026-03-29",{"date":205,"type":42},"2026-04-02",{"date":207,"type":21},"2026-09-01",{"date":209,"type":21},"2027-06-01",{"name":48,"class":49},{"id":212,"slug":213,"hasResults":11,"nctId":214,"briefTitle":215,"officialTitle":216,"acronym":4,"eligibilityCriteria":217,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":218,"targetDuration":4,"studyType":22,"phases":220,"briefSummary":221,"conditions":222,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":203,"lastUpdatePostDateStruct":223,"startDateStruct":224,"completionDateStruct":226,"leadSponsor":228,"locationsCount":50},"100427889","posturecheck-a-vision-based-compensatory-posture-detection-tool-for-robot-assisted-upper-limb-therapy-100427889","NCT04851886","PostureCheck: A Vision-based Compensatory-posture-detection Tool for Robot-assisted Upper-limb Therapy","PostureCheck: A Vision-based Compensatory-posture-detection Tool to Enhance Performance of the BURT Upper-extremity Stroke-therapy","Inclusion Criteria:\n\n* Have had a history of ischemic cerebrovascular accident (CVA) within middle cerebral artery (MCA) or anterior cerebral artery (ACA) territory\n* CVA occurred between six months and six years ago\n* Moderate to severe UE impairment, FMA-UE score between 15 and 45\n* Mini-Mental State Examination (MMSE) score \\>23 and being able to safely follow three-step commands\n\nExclusion Criteria:\n\n* Advanced musculoskeletal pathology or recent fractures in the impaired UE\n* Previous diagnosis of neurological diseases other than stroke\n* Severe limitation of passive range of motion or spasticity (Modified Ashworth Scale for spasticity at \\\u003C3 for UE muscles)\n* Hemorrhagic CVA or involvement of the posterior cerebral artery\n* Aphasia sufficient to limit ability to express needs or discomfort verbally or non-verbally\n* Impaired visual acuity (Severe visual impairments as assessed by the NIH Stroke Scale Visual Field subscale. (score \\>0))\n* Severe hemispatial neglect as assessed by the Line Bisection Test (score \\>2)\n* Severely impaired trunk control (\\\u003C4)\n* Individuals who present with the following on the intended limb:\n* Open wounds\n* Fragile skin\n* Under contact precautions due to an active infection\n* Participation in another therapy focused on recovery of the impaired arm\n* Subjects with cardiac pacemakers, electronic pumps or any other implanted medical devices, that are not US-certified\n* Any Condition that would prevent safe use of the Burt system; such as proprioceptive deficits that impair the ability to process haptic or visual feedback, or unstable shoulder joint as assessed by physical examination\n* Current pregnancy (self-report)\n* The concern is strictly towards women who are in the 2nd or 3rd trimester and the eventuality of the arm of the BURT accidentally impacting the woman's belly. The system does have safety features (including a virtual safety wall, to keep the device away from the patient's body) but we are taking this as an extra precaution against any potential harm",{"count":219,"type":21},42,[24],"The overall objective of this study is to assess whether robot-assisted upper-limb group rehabilitation can be effectively delivered by using a camera-based system equipped with machine learning algorithms to track the quality of the exercise performance and provide feedback accordingly. To address this question, we plan to carry out a randomized clinical trial to compare outcomes in subjects receiving robot-assisted upper-limb rehabilitation during individual (i.e., one-on-one) sessions and in subjects receiving robot-assisted upper-limb rehabilitation during group (i.e., up to three subjects) sessions.",[27],{"date":205,"type":42},{"date":225,"type":42},"2024-04-26",{"date":227,"type":21},"2026-12-31",{"name":48,"class":49},{"id":230,"slug":231,"hasResults":11,"nctId":232,"briefTitle":233,"officialTitle":234,"acronym":235,"eligibilityCriteria":236,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":237,"targetDuration":4,"studyType":22,"phases":239,"briefSummary":240,"conditions":241,"keywords":243,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":250,"lastUpdatePostDateStruct":251,"startDateStruct":253,"completionDateStruct":255,"leadSponsor":257,"locationsCount":258},"100556179","low-oxygen-therapy-to-enhance-walking-recovery-after-sci-100556179","NCT06521723","Low Oxygen Therapy to Enhance Walking Recovery After SCI.","Breathing Low Oxygen to Enhance Spinal Stimulation Training and Functional Recovery for Aging Adults With Chronic SCI: The BO2ST-II Trial","BO2ST-II","Inclusion Criteria:\n\n* 18 to 80 years of age\n* medically stable with medical clearance from study physician to participate\n* SCI at or below C1 and at or above L2 with at least some sensory or motor function preserved below the neurologic level\n* non-progressive etiology of spinal injury\n* American Spinal Injury Association (ASIA) scores of C-D at initial screen\n* ambulatory (able to complete the 10-meter walk test without support from another person)\n* chronic injury (define as \\> 12 months post-injury) to avoid potential for spontaneous neurological plasticity and recovery\n\nExclusion Criteria:\n\n* severe concurrent illness or pain, including unhealed decubiti, severe neuropathic or chronic pain syndrome, severe infection (e.g., urinary tract), hypertension, cardiovascular disease, pulmonary disease, severe osteoporosis, active heterotopic ossification in the lower extremities, severe systemic inflammation\n* \\\u003C 24 on Mini-Mental Exam\n* severe recurrent autonomic dysreflexia\n* history of severe cardiovascular\u002Fpulmonary complications including hypertension (systolic blood pressure \\> 150 mmHg)\n* pregnancy because of unknown effects of AIH or tSTIM on a fetus (individuals of childbearing potential will not otherwise be excluded)\n* botulinum toxin injections in lower extremity muscles within the prior three months\n* history of tendon or nerve transfer surgery in the lower extremity\n* untreated severe sleep-disordered breathing characterized by uncontrolled hypoxia and sleep fractionation that may impact the outcome of this study.\n* active implanted devices (e.g., intrathecal baclofen pump)\n* receiving concurrent electrical stimulation\n* motor threshold evoked by transcutaneous spinal stimulation \\>200 mA",{"count":238,"type":21},60,[24],"The purpose of this study is to determine how combining bouts of low oxygen, transcutaneous spinal cord stimulation, and walking training may improve walking function for people with chronic spinal cord injury of different age groups.",[242],"Spinal Cord Injuries",[244,112,245,246,247,248,249],"Walk","Strength","Movement","Low oxygen","Electrical stimulation","Gait training","2026-03-18",{"date":252,"type":42},"2026-03-20",{"date":254,"type":42},"2025-06-06",{"date":256,"type":21},"2028-09-30",{"name":48,"class":49},2,{"id":260,"slug":261,"hasResults":11,"nctId":262,"briefTitle":263,"officialTitle":264,"acronym":265,"eligibilityCriteria":266,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":267,"enrollmentInfo":268,"targetDuration":4,"studyType":22,"phases":269,"briefSummary":270,"conditions":271,"keywords":272,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":250,"lastUpdatePostDateStruct":277,"startDateStruct":278,"completionDateStruct":280,"leadSponsor":281,"locationsCount":258},"100482520","combination-therapy-to-improve-sci-recovery-100482520","NCT05563103","Combination Therapy to Improve SCI Recovery.","Breathing Low Oxygen to Enhance Spinal Stimulation Training and Functional Recovery in Persons With Chronic SCI: The BO2ST Trial","BO2ST","Inclusion Criteria:\n\n* 18 to 70 years of age\n* medically stable with medical clearance from study physician to participate\n* SCI at or below C2 (phrenic sparing) and at or above L2 with at least some sensory or motor function preserved below the neurologic level\n* non-progressive etiology of spinal injury\n* American Spinal Injury Association (ASIA) scores of C-D at initial screen\n* ambulatory (able to complete the 10-meter walk test without support from another person)\n* chronic injury (define as \\> 12 months post-injury) to avoid potential for spontaneous neurological plasticity and recovery\n\nExclusion Criteria:\n\n* severe concurrent illness or pain, including unhealed decubiti, severe neuropathic or chronic pain syndrome, severe infection (e.g., urinary tract), hypertension, cardiovascular disease, pulmonary disease, severe osteoporosis, active heterotopic ossification in the lower extremities, severe systemic inflammation\n* \\\u003C 24 on Mini-Mental Exam\n* severe recurrent autonomic dysreflexia\n* history of severe cardiovascular\u002Fpulmonary complications including hypertension (systolic blood pressure \\> 150 mmHg)\n* pregnancy because of unknown effects of AIH or tSTIM on a fetus (individuals of childbearing potential will not otherwise be excluded)\n* botulinum toxin injections in lower extremity muscles within the prior three months\n* history of tendon or nerve transfer surgery in the lower extremity\n* untreated severe sleep-disordered breathing characterized by uncontrolled hypoxia and sleep fractionation that may impact the outcome of this study.\n* active implanted devices (e.g., intrathecal baclofen pump)\n* receiving concurrent electrical stimulation\n* motor threshold evoked by transcutaneous spinal stimulation \\>200 mA","70 Years",{"count":238,"type":21},[24],"The purpose of this study is to determine how combining bouts of low oxygen, transcutaneous spinal cord stimulation, and walking training may improve walking function for people with chronic spinal cord injury.",[242],[244,112,245,246,273,274,275,276],"Spinal cord injury","low oxygen","electrical stimulation","walking training",{"date":252,"type":42},{"date":279,"type":42},"2023-01-17",{"date":98,"type":21},{"name":48,"class":49},{"id":283,"slug":284,"hasResults":11,"nctId":285,"briefTitle":286,"officialTitle":287,"acronym":4,"eligibilityCriteria":288,"healthyVolunteers":289,"sex":16,"minAge":17,"maxAge":290,"enrollmentInfo":291,"targetDuration":4,"studyType":22,"phases":293,"briefSummary":294,"conditions":295,"keywords":296,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":250,"lastUpdatePostDateStruct":302,"startDateStruct":303,"completionDateStruct":305,"leadSponsor":307,"locationsCount":50},"100233990","effects-of-breathing-mild-bouts-of-low-oxygen-on-limb-mobility-after-spinal-injury-100233990","NCT02323945","Effects of Breathing Mild Bouts of Low Oxygen on Limb Mobility After Spinal Injury","Mechanisms of Intermittent Hypoxia-induced Motor Recovery in Persons With SCI","Inclusion Criteria:\n\n* Age 18 and 75 years (the latter to reduce likelihood of heart disease)\n* Medical clearance to participate\n* Lesion at or below C2 and above T12 with non-progressive etiology\n* Classified as motor-incomplete with visible volitional leg movement\n* Injury greater than 1 year\n\nExclusion Criteria:\n\n* Concurrent severe medical illness (i.e., infection, cardiovascular disease, ossification, recurrent autonomic dysreflexia, unhealed decubiti, and history of pulmonary complications)\n* Pregnant women because of the unknown affects of AIH on pregnant women and fetus\n* History of seizures, brain injury, and\u002For epilepsy\n* Undergoing concurrent physical therapy\n* Diabetes\n* Cirrhosis\n* Caffeine and\u002For NSAID allergies or intolerances",true,"75 Years",{"count":292,"type":21},44,[24],"Accumulating evidence suggests that repeatedly breathing low oxygen levels for brief periods (termed intermittent hypoxia) is a safe and effective treatment strategy to promote meaningful functional recovery in persons with chronic spinal cord injury (SCI). The goal of the study is to understand the mechanisms by which intermittent hypoxia enhances motor function and spinal plasticity (ability of the nervous system to strengthen neural pathways based on new experiences) following SCI.",[242],[297,298,299,300,301],"acute intermittent hypoxia","incomplete spinal cord injury","strength","walking","breathing",{"date":252,"type":42},{"date":304,"type":4},"2014-10",{"date":306,"type":21},"2027-11",{"name":48,"class":49},{"id":309,"slug":310,"hasResults":11,"nctId":311,"briefTitle":312,"officialTitle":312,"acronym":4,"eligibilityCriteria":313,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":314,"enrollmentInfo":315,"targetDuration":4,"studyType":22,"phases":316,"briefSummary":317,"conditions":318,"keywords":319,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":321,"lastUpdatePostDateStruct":322,"startDateStruct":324,"completionDateStruct":326,"leadSponsor":328,"locationsCount":50},"100555658","yoga-breath-training-to-improve-cardiorespiratory-synchrony-in-spinal-cord-injury-100555658","NCT06514950","Yoga Breath Training to Improve Cardiorespiratory Synchrony in Spinal Cord Injury","Inclusion Criteria:\n\n* Spinal cord injury\n* American Spinal Injury Association Impairment Scale (AIS) score of A, B, or C\n* Aged 18-60 years\n* Wheelchair user\n* Medically stable and able to follow directions\n* Body mass index of 18.5 - 35 kg\u002Fm2\n\nExclusion Criteria:\n\n* Resting blood pressure of \\>140\u002F90 mmHg\n* Current use of tobacco or cardioactive medications (except medication to support blood pressure)\n* Significant arrhythmia\n* Bleeding disorder\n* Pulmonary disease\n* Coronary artery disease\n* Diabetes\n* Renal disease\n* Cancer\n* Epilepsy or other neurological diseases\n* Current use of CPAP\u002FBIPAP\n* Has smartphone or device incompatible with the PranaTM application","60 Years",{"count":82,"type":21},[24],"The goal of this interventional study is to understand how regular yogic breathing practice, particularly a slow resistive yogic breathing technique called Ujjayi, would benefit individuals between the ages of 18 and 60 with spinal cord injuries. Previously yogic breathing has shown to improve respiratory function and sleep- we'd like to explore this further.\n\nThe main questions this study aims to answer are:\n\n* How does Ujjayi breathing affect breathing patterns in individuals with spinal cord injuries?\n* How does Ujjayi breathing affect lung function in individuals with spinal cord injuries?\n* How does Ujjayi breathing affect the part of the nervous system responsible for ventilatory control in individuals with spinal cord injuries?\n* How does Ujjayi breathing affect ventilatory perfusion (how well air and blood flow match in the lungs for efficient gas exchange) in individuals with spinal cord injuries?\n* How does Ujjayi breathing affect sleep quality in individuals with spinal cord injuries?\n\nParticipants will undergo six weeks of training in Ujjayi breathing. Before and after this period, they will visit the lab for measurements of blood pressure, pulse, blood oxygen levels, and breathing. They will also perform several tests:\n\n* Pulmonary function testing to assess lung capacity and respiratory muscle strength.\n* Pace breathing frequency to four pre-recorded audio files at various breathing rates.\n* Breathing exercises involving higher levels of carbon dioxide for a short time.\n* Breathing exercises involving lower levels of oxygen for a short time.\n* At-home sleep evaluation.\n\nBetween the two laboratory testing sessions, participants will practice yogic resistance breathing (Ujjayi breathing) for six weeks.",[242],[320],"SCI, Ujjayi, yogic breathing, pranayama","2026-03-03",{"date":323,"type":42},"2026-03-05",{"date":325,"type":42},"2024-08-01",{"date":327,"type":21},"2027-04-01",{"name":48,"class":49},{"id":330,"slug":331,"hasResults":11,"nctId":332,"briefTitle":333,"officialTitle":333,"acronym":4,"eligibilityCriteria":334,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":335,"targetDuration":4,"studyType":22,"phases":337,"briefSummary":338,"conditions":339,"keywords":342,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":346,"lastUpdatePostDateStruct":347,"startDateStruct":349,"completionDateStruct":351,"leadSponsor":353,"locationsCount":50},"100378335","noninvasive-brain-stimulation-for-treating-carpal-tunnel-syndrome-100378335","NCT04206215","Noninvasive Brain Stimulation for Treating Carpal Tunnel Syndrome","Inclusion Criteria:\n\n1. Able to provide informed consent to participate in the study\n2. Subjects between 18 to 80 years old\n3. Having symptomatic CTS spreading within or beyond the median nerve distribution (demonstrating 'extra-median spread'), involving at least 1 wrist, with chronic pain as defined by International Association for the Study of Pain (existing pain for at least 6 months and having pain on at least half the days in the past 6 months with an average of at least a 3 on a 0-10 VAS scale).\n4. Pain resistant to first line therapies of chronic pain (pain still present at lower levels most of the time following therapy)\n5. Must have the ability to feel pain as self-reported.\n\nExclusion Criteria:\n\n1. Subject is pregnant\n2. Contraindications to tDCS+TUS:\n\n   1. intracranial metal implant\n   2. implanted brain medical devices\n3. History of alcohol or drug abuse within the past 6 months as self-reported\n4. Use of carbamazepine within the past 6 months as self-reported\n5. Suffering from major depression (with a PHQ-9 score of ≥20)\n6. History of neurological disorders involving stroke, brain tumors, or epilepsy with residual neurological symptoms as self-reported (note patients will also be evaluated via EEG at baseline about 1 week prior to stimulation and any patient showing abnormal EEG activity will be removed))\n7. History of unexplained fainting spells as self-reported\n8. History of head injury resulting in more than a momentary loss of consciousness as self-reported and with current neurological deficits\n9. History of intracranial neurosurgery as self-reported",{"count":336,"type":21},95,[24],"The purpose of this study is to assess the effects of tDCS in combination with TUS for the treatment of pain in subjects with Carpal Tunnel Syndrome. The investigators hypothesize that there will be a decrease in pain levels with active stimulation, when compared to sham stimulation.",[340,341],"Chronic Pain","Carpal Tunnel Syndrome",[343,344,345],"transcranial Direct Current Stimulation","Transcranial Ultrasound","Noninvasive brain stimulation","2026-02-18",{"date":348,"type":42},"2026-02-20",{"date":350,"type":42},"2021-04-16",{"date":352,"type":21},"2027-02-28",{"name":48,"class":49},{"id":355,"slug":356,"hasResults":11,"nctId":357,"briefTitle":358,"officialTitle":359,"acronym":360,"eligibilityCriteria":361,"healthyVolunteers":289,"sex":16,"minAge":362,"maxAge":314,"enrollmentInfo":363,"targetDuration":4,"studyType":364,"phases":4,"briefSummary":365,"conditions":366,"keywords":368,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":372,"lastUpdatePostDateStruct":373,"startDateStruct":375,"completionDateStruct":377,"leadSponsor":378,"locationsCount":50},"100622546","linked-outcomes-in-various-eeg-hyperscanning-setups-100622546","NCT07385027","Linked Outcomes in Various EEG-Hyperscanning Setups","LOVEH: Linked Outcomes in Various EEG-Hyperscanning Setups","LOVEH","Inclusion Criteria\n\n1. Healthy volunteers in a romantic partnership for at least 6 months.\n2. 20-60 years of age\n3. Ability to fully understand and consent to study procedures.\n4. Fluent in English\n5. Are on stable doses of medication for 30 days prior to entering the study and agree not to change medications or dosages during the trial.\n\nExclusion Criteria:\n\n1. Presence of any contraindications to EEG scanning.\n2. Illicit drug or opioid use.\n3. Epilepsy, seizures provoked by lights or a prior history of seizures.\n4. Presence of any illness that is judged to interfere with the trial. For example: severe psychiatric disorders according to the DSM-IV manual.\n5. Current chronic pain conditions.\n6. Unwillingness to be audio recorded.\n7. Unwillingness to receive brief experimental pain on the lower left leg.\n8. Unwillingness to withhold from consuming marijuana 48 hours prior to scans.\n9. Unwillingness to withhold from consuming nicotine 4 hours prior to scans.\n10. Any impairment, activity, or situation that in the judgment of the Study Coordinator or Principal Investigator would prevent satisfactory completion of the study protocol.","20 Years",{"count":163,"type":21},"OBSERVATIONAL","The goal of this observational study is to investigate how brains of healthy controls respond when they interact with their romantic partner compared to when they interact with a stranger. The main goals are:\n\n* Explore how two people's brains interact with each other by recording brain activity at the same time (a method called \"hyperscanning\") using electroencephalography (EEG). Using hyperscanning, this study will compare brain-to-brain communication in romantic couples versus strangers, both when they are together in person and when they are interacting remotely.\n* Test a computational model that will help explain how this brain-to-brain communication works, using real data from the brain activity EEG recordings.\n* Explore whether factors such as age, gender, how aware people are of their own body sensations, and their level of attachment influence brain-to-brain communication.\n\nResearchers will compare brain-to-brain communication in romantic couples versus strangers, both when they are together in person and when they are interacting remotely to see which factors effect brain-to-brain communication.\n\nEnrolled participants will:\n\n* Complete a consent visit with their romantic partner where they will sign a consent form and have their pain sensitivity assessed.\n* Fill out sets of questionnaires assessing their romantic relationship, their personality, and other traits.\n* Complete two EEG scans, one with their romantic partner and one with a stranger. At both scans they will conduct a pain task, a communication task, and a light stimulation task.",[367],"Brain to Brain Communication",[369,370,367,371],"Hyperscanning","EEG","Healthy Control","2026-01-29",{"date":374,"type":42},"2026-02-03",{"date":376,"type":42},"2025-12-12",{"date":175,"type":21},{"name":48,"class":49},{"id":380,"slug":381,"hasResults":11,"nctId":382,"briefTitle":383,"officialTitle":383,"acronym":384,"eligibilityCriteria":385,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":386,"enrollmentInfo":387,"targetDuration":4,"studyType":22,"phases":389,"briefSummary":390,"conditions":391,"keywords":395,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":399,"lastUpdatePostDateStruct":400,"startDateStruct":402,"completionDateStruct":404,"leadSponsor":406,"locationsCount":50},"100568857","treatment-of-post-traumatic-knee-osteoarthritis-with-extracorporeal-shockwave-therapy-100568857","NCT06686680","Treatment of Post Traumatic Knee Osteoarthritis With Extracorporeal Shockwave Therapy","PTOA Knee","Inclusion Criteria:\n\n* Previous ACL reconstruction using an autograft or allograft in the knee with PTOA\n* Minimum of one year following ACL reconstruction surgery\n* Between ages of 18 and 55\n* No clear contraindication to complete protocol including mechanical symptoms which would limit ability to complete the study\n* Score on KOOS for 2 of 4 domains (pain, symptoms, activities of daily living (ADL), quality of life (QOL)) of 85 or lower\n* Primary pain is coming from the knee\n* Diagnosis of PTOA based on clinical diagnosis and confirmation with radiographic evidence by a medical professional prior to study enrollment. If individuals have suspected OA based on impairments such as pain, they must have a score on KOOS for 2 of 4 domains (pain, symptoms, activities of daily living (ADL), quality of life (QOL)) of 85 or lower to participate in the study.\n\nExclusion Criteria:\n\n* Have previously received injections to the knee joint within the past 3 months\n* Women who are pregnant or those who are planning to become pregnant. This is due to the fact that pregnancy will reduce participants activity after the treatment and the safety concerns related to shockwave treatment. - Participants with neuropathy affecting sensation to pain\n* Participants with a known underlying cardiac disease that could be affected by shockwave therapy\n* Chronic rheumatological conditions, immunodeficiency, severe asthma, connective tissue disorder (i.e. Ehlers-Danlos Syndrome), or other medical conditions (ex. active malignancy, severe asthma) outside of PTOA that are known to impact inflammatory state or requiring chronic use of oral or intravenous immune modulatory medications. Asthma requiring use of inhalers only is not an exclusion criteria\n* Neuropathy diagnosis that can affect response to pain\n* No active use of oral steroids or anti-inflammatories at the time of enrollment\n* Have bilateral ACL injury or reconstruction surgery, or have had ACL revision surgery\n* No active malignancy and at least five years in remission\n* Previous ESWT treatment using study treatment devices for management of knee osteoarthritis\n* Have a pacemaker, bone screws, or any other metal implants that would prohibit participation in an MRI scan or EWST\n* Non-English speaking individuals","55 Years",{"count":388,"type":21},70,[24],"This study is recruiting current or former athletes who had ACL reconstruction surgery over a year ago and have been diagnosed with knee osteoarthritis (OA). We are doing the research to investigate the effects of extracorporeal shockwave therapy (ESWT) on pain, function, biomechanics, knee range of motion and strength, inflammation, and joint structure and integrity of the knee.",[392,393,394],"Knee Osteoarthristis","ACL Injuries","Post-Traumatic",[396,397,398],"Post-traumatic Knee Osteoarthritis","Extracorporeal shockwave therapy","acl","2025-12-03",{"date":401,"type":42},"2025-12-04",{"date":403,"type":42},"2025-04-01",{"date":405,"type":21},"2026-09",{"name":48,"class":49},{"id":408,"slug":409,"hasResults":11,"nctId":410,"briefTitle":411,"officialTitle":412,"acronym":4,"eligibilityCriteria":413,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":414,"enrollmentInfo":415,"targetDuration":4,"studyType":22,"phases":417,"briefSummary":418,"conditions":419,"keywords":422,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":426,"lastUpdatePostDateStruct":427,"startDateStruct":429,"completionDateStruct":431,"leadSponsor":433,"locationsCount":50},"100577350","a-novel-wrist-wearable-sensor-system-to-promote-hemiparetic-upper-extremity-use-in-subacute-stroke-survivors-100577350","NCT06797154","A Novel Wrist Wearable Sensor System to Promote Hemiparetic Upper Extremity Use in Subacute Stroke Survivors","A Novel Wrist Wearable Sensor System to Promote Hemiparetic Upper Extremity Use in Home Daily Life of Subacute Stroke Survivors","Inclusion Criteria:\n\n* Male or female, 18-85 years of age at the time of enrollment\n* Anterior circulation ischemic stroke at least 1 month and no more than 6 months prior to study enrollment;\n* Unilateral upper extremity hemiparesis as characterized by initial scores on upper limb subtest of the Fugl-Meyer Assessment (FMA-UE) between 20 and 45;\n* Intact cognitive function to understand the study procedures and goal setting (MMSE score above 23 and able to follow 3step command) ;\n* Owning a smartphone (iOS or Android) and being familiar and comfortable with and owning a tablet or smartphone\n* SAFE score equal or greater than 5\n\nExclusion Criteria:\n\n* Severe spasticity (defined as a Modified Ashworth scale score of 3 or more) that would prevent safe performance of UE tasks;\n* Visual impairments as assessed by the NIH Stroke Scale Visual Field subscale (only subjects with no visual loss will participate in the study); or hemispatial neglect that would impair the subject ability to see the feedback on the app screen (as assessed with the Mesulum cancellation test);\n* Individuals with open wounds or recent fracture (less than 3 months) in the upper extremity, fragile skin or active infection;\n* Upper-extremity orthopedic injuries or severe pain resulting in movement limitations;\n* Diagnosis of other neurological disease; (i.e., Parkinson's disease, multiple sclerosis, ...);\n* Severe proprioceptive deficits that impair the ability to process the vibration feedback, as assessed by physical examination during screening;\n* Not understanding spoken or written English;\n* Contralateral motor deficits as assessed by clinical examination;\n* Brainstem and cerebellar stroke.","85 Years",{"count":416,"type":21},88,[24],"The proposed study is a two-arm randomized clinical trial designed to assess the effects of the StrokeWear system on clinical outcomes over a period of 6-months in subacute stroke survivors. The Intervention group will use StrokeWear system in combination to a motor and behavioral home intervention whereas the Control group will follow usual care which consists of a home-exercise plan (HEP).",[27,420,421],"Stroke Sequelae","Hemiparesis;Poststroke\u002FCVA",[423,424,425],"StrokeWear","Biosensics","Behavioral Intervention","2025-11-21",{"date":428,"type":42},"2025-11-28",{"date":430,"type":42},"2025-08-08",{"date":432,"type":21},"2026-08-31",{"name":48,"class":49},{"id":435,"slug":436,"hasResults":11,"nctId":437,"briefTitle":438,"officialTitle":439,"acronym":4,"eligibilityCriteria":440,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":414,"enrollmentInfo":441,"targetDuration":4,"studyType":22,"phases":443,"briefSummary":445,"conditions":446,"keywords":447,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":426,"lastUpdatePostDateStruct":450,"startDateStruct":451,"completionDateStruct":453,"leadSponsor":455,"locationsCount":50},"100487423","phase-2-novel-wrist-sensor-system-to-promote-hemiparetic-arm-use-in-home-daily-life-of-chronic-stroke-survivors-100487423","NCT05626894","Novel Wrist Sensor System to Promote Hemiparetic Arm Use in Home Daily Life of Chronic Stroke Survivors","A Novel Wrist Wearable Sensor System to Promote Hemiparetic Upper Extremity Use in Home Daily Life of Chronic Stroke Survivors","Inclusion Criteria:\n\n* Male or female, 18-85 years of age at the time of enrollment;\n* Anterior circulation ischemic stroke at least 6 months and up to 5 years prior to study enrollment;\n* Unilateral upper extremity hemiparesis as characterized by initial scores on upper limb subtest of the Fugl-Meyer Assessment (FMA-UE) between 20 and 45;\n* Intact cognitive function to understand the study procedures and goal setting (MMSE score above 23 and able to follow 3 step command);\n* Being familiar and comfortable with the use of a tablet or smartphone.\n\nExclusion Criteria:\n\n* Severe spasticity (defined as a Modified Ashworth scale score of 3 or more) that would prevent safe performance of UE tasks;\n* Visual impairments as assessed by the NIH Stroke Scale Visual Field subscale (only subjects with no visual loss will participate in the study); or hemispatial neglect that would impair the subject ability to see feedback on the app screen (as assessed with the star cancellation test);\n* Individuals with open wounds or recent fracture (less than 3 months) in the UE, fragile skin or active infection as evaluated by the study therapist;\n* Individuals currently enrolled in a UE rehabilitation program (i.e., OT, research study)\n* Upper-extremity orthopedic injuries or severe pain resulting in movement limitations;\n* Diagnosis of other neurological disease (i.e., Parkinson's disease, multiple sclerosis, ...);\n* Severe proprioceptive deficits that impair the ability to process the vibration feedback, as assessed by physical examination during screening as assessed by the study therapist;\n* Not understanding spoken or written English;\n* Recent (less than 3 months) Botox injection in the UE or plan to undergo injections during the study timeline;\n* Contralateral motor deficits as assessed by clinical examination;\n* Brainstem and cerebellar stroke.",{"count":442,"type":21},32,[444],"PHASE2","The proposed study is a two-arm randomized clinical trial designed to assess the effects of the StrokeWear system on clinical outcomes over a period of 6-months in chronic stroke survivors. The Intervention group will use StrokeWear system in combination to a motor and behavioral home intervention whereas the Control group will follow usual care which consists of a home-exercise plan (HEP).",[27,420,421],[423,448,449],"BioSensics","Behavioral intervention",{"date":428,"type":42},{"date":452,"type":42},"2025-03-20",{"date":454,"type":21},"2026-09-30",{"name":48,"class":49},{"id":457,"slug":458,"hasResults":11,"nctId":459,"briefTitle":460,"officialTitle":460,"acronym":461,"eligibilityCriteria":462,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":80,"enrollmentInfo":463,"targetDuration":4,"studyType":22,"phases":465,"briefSummary":466,"conditions":467,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":469,"lastUpdatePostDateStruct":470,"startDateStruct":472,"completionDateStruct":474,"leadSponsor":476,"locationsCount":50},"100543825","synergistic-gut-brain-axis-modulation-via-vagal-stimulation-and-support-therapy-in-functional-dyspepsia-100543825","NCT06360900","Synergistic Gut-brain Axis Modulation Via Vagal Stimulation and Support Therapy in Functional Dyspepsia","CONVERGE","Inclusion Criteria:\n\nAge 18-65 years old (inclusive)\n\n* Ability to give written consent and participate in behavioral intervention in English\n* Willingness to attend weekly treatment sessions over live video, daily self-administered transcutaneous auricular vagus nerve stimulation (taVNS) sessions, and engage in homework during treatment\n* Avoidance of alcohol, nicotine, and caffeine for 24 hours prior to study session\n* Diagnosis according to the Rome IV criteria for both epigastric pain syndrome and postprandial distress syndrome subtypes\n* Stable medical treatment for functional dyspepsia (FD) during 1 month before the study and during the study period\n\nExclusion Criteria:\n\n* Previous receipt of cognitive behavioral therapy (CBT) for gastrointestinal symptoms\n* Enteral or parenteral feeding\n* Previous gastrointestinal surgery, electrolyte disturbances, kidney dysfunction, renal insufficiency, or iron overload disorders\n* Estimated Glomerular Filtration Rate (eGFR) \\\u003C 60\n* Medications that affect gastrointestinal motility in addition to medications or products containing tetrahydrocannabinol (THC) will be stopped at least 7 days prior to the start of the study and for the duration of the study. However, anti-depressants (SSRI's, TCA's) may be allowed in order to reduce the risk of worsening neuropsychiatric disease, though it will be up to the study team and the Principal Investigator whether subjects on anti-depressants will be able to participate in the study\n* Intellectual disability by history\n* Diabetes, mitochondrial disease, severe autonomic dysfunction, and small fiber polyneuropathy\n* No active clinical acupuncture therapy\n* Illicit drugs or opioid usage\n* History of arrhythmias\n* Current pregnancy\u002Fbreastfeeding\n* Contraindications for magnetic resonance imaging (MRI) (implanted ferromagnetic objects, claustrophobia)\n* Weight \\> 450 lbs. (limit of the MRI table)\n* Allergy to pineapple (used in the test meal during MRI)\n* Any other condition interfering with study requirements, according to the Investigator",{"count":464,"type":21},80,[24],"The study aims at evaluating physiological and patient-reported outcomes for a dual intervention approach including a stimulation device and support therapy in patients with functional dyspepsia.",[468],"Functional Dyspepsia","2025-11-04",{"date":471,"type":42},"2025-11-06",{"date":473,"type":42},"2025-10-29",{"date":475,"type":21},"2029-03",{"name":48,"class":49},{"id":478,"slug":479,"hasResults":11,"nctId":480,"briefTitle":481,"officialTitle":482,"acronym":4,"eligibilityCriteria":483,"healthyVolunteers":289,"sex":16,"minAge":17,"maxAge":484,"enrollmentInfo":485,"targetDuration":4,"studyType":22,"phases":486,"briefSummary":487,"conditions":488,"keywords":490,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":494,"lastUpdatePostDateStruct":495,"startDateStruct":497,"completionDateStruct":499,"leadSponsor":501,"locationsCount":50},"100579629","evaluating-q-collar-effects-on-brain-blood-flow-control-during-exercise-100579629","NCT06826781","Evaluating Q-Collar Effects on Brain Blood Flow Control During Exercise","Evaluating Q-Collar Effects on Cerebrovascular Control in Response to Exercise","Inclusion Criteria:\n\n* healthy individuals between the ages of 18 to 30 years old\n\nExclusion Criteria:\n\n* History of concussion or other brain injury resulting in loss or alteration in consciousness or other change in cognition within 24 months of study visit\n* High cardiac risk according to the American College of Sports Medicine (ACSM)11\n* Ongoing active treatment with a cardioactive drug\n* Inability to stand from a seated position unassisted\n* History of a neurologic disorder or neurosurgery intervention\n* Pregnancy\n* Any current, serious, chronic medical or psychiatric disease that in the Principal Investigator's or co-investigator's judgment may interfere with study participation or data integrity\n* Unable or unwilling to provide informed consent","30 Years",{"count":82,"type":21},[24],"The goal of this clinical trial is to learn how the FDA-cleared Q-Collar device affects brain blood flow regulation during rest and exercise in healthy adults. The main questions this study aims to answer are:\n\n1. How does the Q-Collar affect brain blood flow when there are quick changes in blood pressure, like when standing up quickly, or when breathing against resistance?\n2. How does the Q-Collar affect brain blood flow during exercise?\n\nResearchers will compare sessions where participants wear the Q-Collar to sessions where they do not wear the device to see if the Q-Collar improves brain blood flow during both rest and exercise.\n\nParticipants will:\n\n* Complete two study visits, each 1 to 4 weeks apart.\n* Perform a series of tasks, including standing tests, breathing tests, and exercise on a stationary bike, while their heart rate, brain blood flow, and other body functions are monitored.\n* Wear the Q-Collar during one of the sessions and not wear it during the other session. The order of the sessions will be randomly assigned.",[489],"Healthy",[491,492,493],"Q-Collar","Cerebrovascular Blood Flow Regulation","Exercise","2025-10-23",{"date":496,"type":42},"2025-10-27",{"date":498,"type":42},"2025-07-23",{"date":500,"type":21},"2026-08-23",{"name":48,"class":49},{"id":503,"slug":504,"hasResults":11,"nctId":505,"briefTitle":506,"officialTitle":507,"acronym":4,"eligibilityCriteria":508,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":80,"enrollmentInfo":509,"targetDuration":4,"studyType":22,"phases":510,"briefSummary":511,"conditions":512,"keywords":513,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":519,"lastUpdatePostDateStruct":520,"startDateStruct":522,"completionDateStruct":524,"leadSponsor":526,"locationsCount":527},"100528215","cognitive-training-to-enhance-brain-concordance-during-acupuncture-100528215","NCT06157866","Cognitive Training to Enhance Brain Concordance During Acupuncture","Cognitive Training to Enhance Brain-to-brain Concordance During Acupuncture","Inclusion Criteria:\n\n* Meet traditional American College of Rheumatology (ACR) criteria for FM as well as the more recent Wolfe et al 2011 criteria\n* Are on stable doses of medication for 30 days prior to entering the study and agree not to change medications or dosages during the trial\n* Ability to fully understand and consent to study procedures\n* Baseline pain intensity of at least 4\u002F10\n* Pain duration of at least 6 months\n\nExclusion Criteria:\n\n* Any longer period of work experience involving pain treatment, pain rehabilitation etc.\n* Presence of any illness that is judged to interfere with the trial. For example: psychiatric disorder according to the DSM-IV manual\n* Presence of any contraindications to fMRI scanning. For example: cardiac pacemaker, metal implants, fear of closed spaces, pregnancy.\n* History of significant head injury\n* Inability to respond accurately to the pain-relieving intervention in the behavioral part of the experiment, indicating a lack of response to the expectancy manipulation. If the healthy volunteer or clinician is not a responder to the behavioral expectancy induction he or she will be excluded.\n* Unwillingness to receive brief experimental pain.\n* Leg pain or health issues that may interfere with the study procedures.\n* Comorbid acute pain condition\n* Comorbid chronic pain condition that is rated by the subject as more painful than fibromyalgia\n* Current use of opioid analgesics\n* Concurrent inflammatory or autoimmune disease\n* Documented peripheral neuropathy\n* Pregnant\n* Any psychiatric disorder involving a history of psychosis (e. g schizophrenia, bipolar disorder, severe personality disorders)\n* History of anxiety disorders or significant anxiety symptoms interfering with fMRI procedures (e.g., panic)\n* Psychiatric hospitalization in the past 6 months\n* Unwillingness to withhold from consuming marijuana 12 hours prior to scans\n* Unwillingness to withhold from consuming nicotine 4 hours prior to scans\n* Any impairment, activity or situation that in the judgment of the Study Coordinator or Principal Investigator would prevent satisfactory completion of the study protocol.\n* Is an actual clinical patient of the clinician subject\n* Recent history of formal meditation-based training",{"count":131,"type":21},[24],"This study will evaluate the impact of a novel non-pharmacological multimodal therapy, a type of approach known to improve pain outcomes and recommended by the Institute of Medicine report for chronic pain management. This study design will also allow the investigators to evaluate a neural model supporting therapeutic alliance for pain outcomes for fibromyalgia.",[87],[514,515,516,517,518],"hyperscan fmri","hyperscan EEG","acupuncture","fibromyalgia","chronic pain","2025-10-22",{"date":521,"type":42},"2025-10-24",{"date":523,"type":42},"2024-02-16",{"date":525,"type":21},"2027-06-30",{"name":48,"class":49},3,{"id":529,"slug":530,"hasResults":11,"nctId":531,"briefTitle":532,"officialTitle":532,"acronym":4,"eligibilityCriteria":533,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":534,"targetDuration":4,"studyType":22,"phases":536,"briefSummary":537,"conditions":538,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":540,"lastUpdatePostDateStruct":541,"startDateStruct":543,"completionDateStruct":544,"leadSponsor":546,"locationsCount":50},"100530940","effects-of-tavns-on-fibromyalgia-pain-100530940","NCT06193317","Effects of taVNS on Fibromyalgia Pain","Inclusion Criteria:\n\n1. Older than 18 years old.\n2. Diagnosis of FM pain according to the American College of Rheumatology (ACR) 2010 criteria (existing pain for more than six months with an average of at least 3 on a 0-10 VAS scale).\n3. must have the ability to feel sensation by Von-Frey fiber on the forearm.\n4. Able to provide informed consent to participate in the study.\n\nExclusion Criteria:\n\n1. Subjects who have unstable medical conditions (e.g., uncontrolled diabetes, uncompensated cardiac issues, heart failure, or chronic obstructive pulmonary disease) or who have functional deficits, as self-reported.\n2. history of substance abuse within the past six months as self-reported (if the subject reports a history of substance abuse, we will confirm using the Diagnostic and Statistical Manual of Mental Disorders (DSM-V) criteria).\n3. Presence of implanted cranial electronic medical devices (e.g., cochlear implants).\n4. pregnancy (as the safety of taVNS in the pregnant population (and children) has not been assessed (though the risk is non-significant), we will exclude pregnant women (and children). Women of child-bearing potential will be required to take a urine pregnancy test during the screening process and every two weeks of stimulation).",{"count":535,"type":21},152,[24],"Transauricular vagus nerve stimulation (taVNS) is a newer delivery system, using a non-invasive stimulation device placed at the ear's concha. TaVNS is a portable, safe, and low-cost intervention, and according to some studies, taVNS may influence nociception and pain perception, which can lead to potential applications for various painful illnesses, including fibromyalgia (FM). This trial aims to investigate the clinical effects of taVNS on pain control in FM subjects.",[539],"Fibromyalgia, Pain","2025-09-15",{"date":542,"type":42},"2025-09-19",{"date":152,"type":21},{"date":545,"type":21},"2029-05-01",{"name":48,"class":49},{"id":548,"slug":549,"hasResults":11,"nctId":550,"briefTitle":551,"officialTitle":551,"acronym":4,"eligibilityCriteria":552,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":553,"targetDuration":4,"studyType":22,"phases":555,"briefSummary":556,"conditions":557,"keywords":558,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":540,"lastUpdatePostDateStruct":561,"startDateStruct":563,"completionDateStruct":565,"leadSponsor":566,"locationsCount":50},"100503231","mechanisms-of-open-and-hidden-placebo-in-stroke-recovery-100503231","NCT05832567","Mechanisms of Open and Hidden Placebo in Stroke Recovery","Inclusion Criteria:\n\n1. Adults with hemiparesis due to chronic stroke\n2. Stroke duration of 6 months or more\n3. Fugl-Meyer scale upper extremity motor assessment score of \\> 11 and ≤ 56\n4. Pre-stroke disability (defined as a score of \\\u003C 3 on the Modified Rankin Scale)\n5. Age 18 or older\n\nExclusion Criteria:\n\n1. Stroke of anterior cerebral artery territory with prefrontal lesion and stroke-related decreased EEG power in the prefrontal cortex\n2. Unable to understand instructions\n3. TMS contraindications: electronic hardware in close contact to the discharging coil such as cochlear implant, internal pulse generator or medical pump\n4. Concurrent unstable medical conditions\n5. A score of 24 or higher on the Hamilton Depression Rating Scale (HDRS)\n6. Joint or paretic extremity pain likely to interfere with assessments\n7. Pregnancy",{"count":554,"type":21},56,[24],"This trial aims to investigate whether placebo in isolation (open and hidden) has a specific neural signature in stroke subjects thus providing a novel mechanism to explain placebo effects that can be used to ultimately enhance stroke rehabilitation therapies.",[27,29],[559,560],"stroke","placebo",{"date":562,"type":42},"2025-09-17",{"date":564,"type":42},"2023-09-11",{"date":65,"type":21},{"name":48,"class":49},{"id":568,"slug":569,"hasResults":11,"nctId":570,"briefTitle":571,"officialTitle":571,"acronym":572,"eligibilityCriteria":573,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":574,"targetDuration":4,"studyType":22,"phases":576,"briefSummary":577,"conditions":578,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":540,"lastUpdatePostDateStruct":580,"startDateStruct":581,"completionDateStruct":583,"leadSponsor":584,"locationsCount":50},"100453718","pragmatic-trial-of-remote-tdcs-and-somatosensory-training-for-phantom-limb-pain-with-machine-learning-to-predict-treatment-response-100453718","NCT05188183","Pragmatic Trial of Remote tDCS and Somatosensory Training for Phantom Limb Pain With Machine Learning to Predict Treatment Response","PLP-EVEREST","Inclusion Criteria:\n\n1. Age - older than 18 years\n2. Limb amputation\n3. Patients who experience PLP regularly (at least once a week)\n4. Pain not attributable to other causes, such as peripheral inflammation\n5. Current chronic pain as defined by an average pain of at least 4 on the numeric rating scale (NRS, 0: no pain, 10: worst imaginable pain)\n\nExclusion Criteria:\n\n1. Any clinically significant or unstable medical or psychiatric disorder\n2. History of substance abuse in the past 6 months (according to the DSM-V criteria for substance use disorder with six or more symptoms)\n3. Uncompensated psychiatric disorder\n4. Previous significant neurological history with current significant neurological deficits\n5. Previous neurosurgical procedure with craniectomy that would affect current distribution of tDCS\n6. Contraindications to tDCS (implanted brain medical devices)",{"count":575,"type":21},290,[24],"The investigators have designed a pragmatic trial of home-based transcranial direct current stimulation (tDCS) for phantom limb pain (PLP), the PLP-EVEREST trial (PLP-EffectiVEness pRagmatic Stimulation Trial) to test a portable device that would reach underrepresented populations and would validate this therapy in a more pragmatic setting. Subjects will be randomized to home-based tDCS of the primary motor cortex (M1) with somatosensory training or usual care only (including their current pharmacological treatments, physical therapy, and occupational therapy). The investigators will therefore test the effectiveness of home-based tDCS and somatosensory training in a real-world, home-based setting. The Investigator will compare patients randomized to this combined strategy vs. usual care alone (subjects from this group will be offered combined treatment at the end of the trial). The investigators hypothesize that the combined strategy will be associated with a significantly larger Cohen's d effect size (at least 1) compared to the control group.",[579],"Phantom Limb Pain",{"date":542,"type":42},{"date":582,"type":42},"2022-09-01",{"date":46,"type":21},{"name":48,"class":49},""]